Industry Symposia
LOOK BACK, THINK FORWARD: ADVANCING PID PATIENT CARE OVER THE YEARS

SYMPOSIUM IS ORGANISED AND SUPPORTED BY Takeda
Wednesday, September 18 | 16:00 – 17:30 | Gold Hall
Chair: Mikko Seppänen (Finland)
16:00-16:10
Welcome and introduction
Mikko Seppänen (Finland)
16:10-16:30
Stop the delay – simplifying diagnosis in PID
Mikko Seppänen (Finland)
16:30-16:50
Growing up with PID – smoothing the transition from pediatrics to adult care
Eline Visser (Netherlands)
16:50-17:10
Comprehensive care – managing PID and cancer
Silvia Sánchez-Ramón (Spain)
17:10-17:25
Q&A
17:25-17:30
Summary and close
Mikko Seppänen (Finland)
INFECTIONS AND SECONDARY IMMUNODEFICIENCY IN HEMATOLOGICAL CANCER: IDENTIFYING PATIENTS AT RISK

SYMPOSIUM IS ORGANISED AND SUPPORTED BY CSL Behring
Thursday, September 19 | 12:45 – 14:15 | Copper Hall
Chair: Donald Vinh (Canada)
12:45-12:55
INTRODUCTION
Donald Vinh (Canada)
12:55–13:15
HEMATOLOGICAL MALIGNANCIES AND SID: WHAT DO WE KNOW?
Donald Vinh (Canada)
13:15-13:35
RISK FACTORS FOR INFECTIONS IN SID: WHAT ARE WE MISSING? RESULTS OF A NEW STUDY
Stephen Jolles (UK)
13:35-13:55
HOW TO MANAGE THE UNIQUE INFECTION RISK PROFILE IN HEMATOLOGICAL MALIGNANCIES
B. Douglas, Smith (US)
13:55-14:15
PATIENT CASE & ROUNDTABLE DISCUSSION
Donald Vinh (Canada), Stephen Jolles (UK) and Douglas Smith (US)
14:15
MEETING CLOSE
Donald Vinh (Canada)
Lunch will be provided
THE CHANGING PICTURE OF SECONDARY IMMUNE DEFICIENCY IN HAEMATOLOGICAL MALIGNANCIES

SYMPOSIUM IS ORGANISED AND SUPPORTTED BY Octapharma
Friday, September 20 | 12:45 – 14:15 | Silver Hall
Chair: Stephen Jolles (UK)
12:45-12:50
Welcome and introduction
Stephen Jolles (UK)
12:50-13:10
What underpins the growth in secondary antibody deficiency?
Stephen Jolles (UK)
13:10-13:30
CD19 CAR-T cells – Implications for the management of secondary immune deficiency
Michael Albert (Germany)
13:30-13:50
Recommendations for the management of secondary hypogammaglobulinaemia
Fabian Hauck (Germany)
13:50-14:10
CLL – An illustrative case of a complex secondary immune deficiency
Jean-François Viallard (France)
14:10-14:15
Discussion and closing remarks
All
Lunch will be provided